IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Holdings in Illumina, Inc. $ILMN

IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 82.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 56,191 shares of the life sciences company’s stock after purchasing an additional 25,344 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Illumina were worth $5,336,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in ILMN. AQR Capital Management LLC boosted its holdings in Illumina by 55.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock valued at $313,290,000 after acquiring an additional 1,174,295 shares during the period. Edmond DE Rothschild Holding S.A. lifted its position in Illumina by 140.1% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock valued at $136,312,000 after purchasing an additional 833,750 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in shares of Illumina by 1,558.0% during the second quarter. Thrivent Financial for Lutherans now owns 728,755 shares of the life sciences company’s stock valued at $69,528,000 after purchasing an additional 684,802 shares during the period. Pacer Advisors Inc. purchased a new stake in shares of Illumina during the third quarter valued at approximately $61,663,000. Finally, Invesco Ltd. grew its holdings in shares of Illumina by 48.9% in the second quarter. Invesco Ltd. now owns 1,353,077 shares of the life sciences company’s stock worth $129,097,000 after purchasing an additional 444,543 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Illumina

In other news, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the transaction, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 2.60% of the company’s stock.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q4 earnings beat — Illumina reported $1.35 GAAP/non‑GAAP EPS (beat consensus) and $1.16B in revenue (above estimates), showing 5% YoY revenue growth for the quarter. This confirms near‑term operating leverage and profitability. Zacks: Tops Q4 Estimates
• Positive Sentiment: FY2026 revenue guide lifted — Illumina gave 2026 revenue guidance of $4.5B–$4.6B (above Street revenue consensus), signaling expected mid-single-digit growth and underlying demand momentum. That revenue guide is a key upside catalyst for FY26. Press Release / Guidance
• Positive Sentiment: Operational tailwinds — Management highlighted clinical consumables growth, expansion into multiomics and margin momentum (non‑GAAP op margin guidance ~23.3–23.5%), supporting durable revenue mix improvement and higher-margin recurring revenue. Yahoo Deep Dive
• Neutral Sentiment: SomaLogic acquisition and dilution — Guidance includes ~$0.18 EPS dilution and ~100bps margin headwind from the recently closed SomaLogic deal; strategic for multiomics but a modest near‑term drag. PR Newswire: Financial Results
• Neutral Sentiment: Full call and disclosures available — The earnings call transcript, slide deck and SEC/press materials are posted for deeper review of segment trends and backlog — useful for modeling revenue cadence and margin drivers. Seeking Alpha Transcript
• Negative Sentiment: FY2025 revenue flat — Full-year 2025 revenue was essentially flat vs. 2024, a disappointment to some investors who had hoped for stronger recovery; this disappointment is the main reason shares are down despite the quarterly beat. Investing.com: Shares Tumble

Illumina Price Performance

ILMN opened at $133.61 on Friday. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $155.53. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. The stock has a fifty day simple moving average of $138.67 and a two-hundred day simple moving average of $115.99. The company has a market cap of $20.42 billion, a price-to-earnings ratio of 29.96, a price-to-earnings-growth ratio of 2.23 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The company’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ILMN shares. Guggenheim increased their price target on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Zacks Research lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. Robert W. Baird set a $109.00 target price on Illumina in a research note on Friday, October 31st. Evercore ISI reaffirmed an “outperform” rating and set a $155.00 price target on shares of Illumina in a research report on Monday, January 5th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $127.18.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.